42 results about "Placenta Growth Factor" patented technology

The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.

The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of placenta growth factor, wherein (b) if the level of the placenta growth factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.

The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and placenta growth factor (PIGF) polypeptide comprising a nucleotide sequence encoding a VEGFR1 component.

The invention discloses essential oil handmade soap with effects of cooling, moisturizing and cleaning skin. The essential oil handmade soap comprises, by weight, 35-45 parts of sodium cocoyl glutamate, 10-15 parts of flower and plant essential oil, 5-8 parts of tea polyphenol, 3-6 parts of lycium barbarum polysaccharide, 1-3 parts of lotus leaf extract, 1-3 parts of radix scrophulariae extract, 12-15 parts of trehalose, 7-10 parts of glutathione, 3-5 parts of vitamins, 30-35 parts of grape seed oil, 15-20 parts of palm kernel oil, 7-10 parts of castor oil, 1-2 parts of olive oil, 1.5-2.5 parts of sodium hydroxide, 5-8 parts of phosphatidylcholine bilayer, 1-2 parts of superoxide dismutase, 0.5-1 part of a placenta growth factor, 2-3 parts of royal jelly, 1-2 parts of 1, 2-propylene glycol, 2-3 parts of hydroxyethyl urea, 1-2 parts of carbomer and 2-3 parts of sodium lactate. The essential oil handmade soap has effects of deep cleaning skin, softening skin, reducing skin pruritus, balancing skin pH, supplying water, fading wrinkles, promoting shrinkage of enlarged pores of skin and keeping water-oil balance.

The present invention relates to a vascular endothelial growth factor fusion protein. The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and / or a placental growth factor (PLGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, the fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases.

The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).

The invention is situated in the field of ocular therapies. In particular it refers to antagonists of placental growth factor for interfering with posterior ocular fibrosis.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

This invention relates to compositions and methods for the treatment or prophylaxis of glaucoma and ocular hypertension, and for lowering of intraocular pressure. The invention provide VEGFR-1 agonists and combinations of vascular endothelial growth factor B (VEGF-B) with placenta growth factor (PLGF), ‘ Secreted protein acidic cysteine-rich’ (SPARC) antagonists, insulin, insulin like growth factor, their isoforms, their analoges, their gene-engineered modifications. Furthermore, the formentioned compositions and combinations are provided for coadministration with antiglaucoma agents, currently in clinical use, for the treatment or prophylaxis of glaucoma and ocular hypertension, for lowering of intraocular pressure, for increasing success rate of surgical procedures for the treatment or prophylaxis of glaucoma, and for preserving retinal ganglion cells.

Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide.

The invention relates to a soluble fms-like tyrosine kinase-1 detection kit as well as a preparation method and application thereof, the inventor detects soluble fms-like tyrosine kinase-1 by adopting a double-antibody sandwich method combined with a magnetic particle chemiluminescence technology, and finds that an immune micro-magnetic particle preparation method optimized by the inventor is adopted. A soluble fms-like tyrosine kinase-1 chemiluminescence immunoassay kit is formed by the prepared placenta growth factor capture antibody magnetic particles and an alkaline phosphatase labeled placenta growth factor detection antibody which is further prepared by the inventor through cross-linking agents DTBP and DTT and a sealing agent MMTS in a specific proportion. According to the present invention, the detection can be automatically completed by using the full-automatic chemiluminescence immunoassay analyzer as the detection tool, the detection performance is significantly improved, the detection sensitivity achieves 0.97 pg / mL, and the detection linear range is wide and can achieve 10-85000 pg / mL. Therefore, the method has a wide detection application prospect.

The invention provides a placenta growth factor quality control product and a preparation method thereof. The placenta growth factor quality control product comprises a placenta growth factor antigen, newborn calf serum, BSA and / or casein, glycerin and / or Tween 80, mannitol and / or xylitol and a preservative. The placenta growth factor quality control product disclosed by the invention is simple in preparation method, high in accuracy, high in precision and good in stability, can be applied to a fluorescence immunoassay platform of a POCT system, and is suitable for placenta growth factor detection kits clinically common on the platform. A quality control substance is provided for placenta growth factor kit evaluation and indoor and interventricular quality evaluation in clinical laboratories.

The invention belongs to the field of biological technique, i.e. gene recombination engineering. Placental growth factors (PLGFs) play important roles in neovascularization and vascular proliferation; however, natural PLGF content in vivo is low and the natural PLGFs have short half-times, thus to extract sufficient entogenous PLGF proteins so as to satisfy the increasingly demands of experimental study and clinical practice is difficult. The invention discloses a method for efficiently expressing, producing and recombining a PLGF system in vitro by gene recombination engineering and cell culture technology and for extracting and purifying the PLGF proteins from expressed supernatant by chromatographic separating technology. The invention also discloses a nonradioactive chemical coupling labeling treatment method for the purified PLGF proteins in vitro. The PLGF proteins (including the unlabeled or the chemical coupling labeled) have wide application in the experimental study and the clinical practice.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

The name of the present invention is vascular endothelial growth factor fusion protein. The present invention relates to fusion proteins that bind to vascular endothelial growth factor (VEGFR) and / or placental growth factor (PlGF). The fusion protein of the present invention comprises (a) the Fc domain of IgG1, wherein two heavy chains are linked by disulfide bonds, and (b) four immunoglobulin domains 2 of VEGFR1, of which two immunoglobulin domains 2 Each heavy chain fused sequentially to the Fc domain of (a). The fusion protein of the present invention has excellent activity of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibitory effect on various cancers and fibroblasts. Therefore, the fusion protein of the present invention can be used to prepare medicaments for treating cancer or eye diseases.

The invention belongs to the field of biological technologies, and more specifically discloses an anti-VEGF / PIGF (vascular endothelial growth factor / placenta growth factor) bispecific antibody as well as a preparation method and an application thereof. The anti-VEGF / PIGF bispecific antibody can be combined with VEGF and PIGF, and can effectively inhibit the formation of tumor internal blood vessels, thereby inhibiting the growth of tumors more effectively.

Process for extracting and purifying the recombinant Placental Growth Factor (PLGF) expressed in inducible prokaryotic expression systems comprising the following steps: I) fermentation of the bacterial cells, II) extraction and purification of the inclusion bodies, III) renaturation of the expressed protein, IV) ion-exchange chromatography, V) reverse-phase chromatography.

The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of an anti-PlGF antibody or fragment thereof.

The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant PLGF protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset. The present invention also provides exemplary recombinant PLGF proteins including monomeric, dimeric and single-chain PLGF proteins.

The invention provides a placental growth factor detection kit and a preparation method thereof, the placental growth factor detection kit comprises: a reagent R1, the reagent R1 comprises a diluent R1 and magnetic beads coated with a placental growth factor antibody, the R1 diluent comprises a first buffer agent, a first surfactant, a first protein, a first preservative and a first salt compound; the reagent R1 comprises a reagent R1 and a reagent R2, the reagent R1 comprises a diluent R2 and an enzyme-labeled placental growth factor antibody, and the diluent R2 comprises a second buffer agent, a second surfactant, a second protein, a second preservative and a second salt compound. According to the placenta growth factor detection kit designed on the basis of a chemiluminescence method, products can be subsequently collected, signals of the products can be tested, and operation is simple and rapid; meanwhile, components of the reagent R1 and the reagent R2 are reasonably compounded, the signal intensity is high, the sensitivity can be further improved, and the test range can be further widened.